A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma-Reference-Cited by-同舟云学术

A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma

Published:2023 Issue: Volume:34 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Micha John P.¹^ORCID,Rettenmaier Mark A.¹^ORCID,Bohart Randy D.²^ORCID,Goldstein Bram H.¹^ORCID

Affiliation:

1. Women’s Cancer Research Foundation, Laguna Beach, CA, USA.

2. Oso Home Care, Inc., Irvine, CA, USA.

Funder

Women’s Cancer Research Foundation

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2023.34.e15

Reference38 articles.

1. Cancer Statistics, 2021

2. First-line treatment of ovarian cancer: questions and controversies to address

3. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review)

4. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

5. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Repositioning for Ovarian Cancer Treatment: An Update;Anti-Cancer Agents in Medicinal Chemistry;2024-05

2. Cancer Stem Cells as a Therapeutic Target: Current Clinical Development and Future Prospective;Stem Cells;2023-12-14

3. Systematic analysis and prediction for disease burden of ovarian cancer attributable to hyperglycemia: a comparative study between China and the world from 1990 to 2019;Frontiers in Medicine;2023-04-13